Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 16, 2006

View Archived Issues

CE Mark for Tag-It Cystic Fibrosis Kit

ActivBiotics and Metaphore Pharmaceuticals complete merger

Pharmacopeia earns milestone payment in Organon collaboration

New multidose study of Riquent planned in lupus patients

Studies show BioThrax plus antibiotics protect animals post anthrax exposure

Japanese licensing deal for Fentanyl Taifun

Corautus Genetics to support study of VEGF-2 in critical limb ischemia

Salix offers development update

Duloxetine 60 mg once daily found safe and effective in fibromyalgia patients

GE-81112 factor B: A novel prokaryotic-specific protein synthesis inhibitor

Human Genome Sciences receives milestone for GSK-716155 IND filing

Mylan and Forest sign nebivolol agreement

Ablynx and Centocor sign Nanobodies agreement

Phase IIa study of ATL-1102 restarts

Safety data review in phase III study of Intercell's Japanese encephalitis vaccine

Russian approvals for HER-2 Protein AutoVac vaccine phase II trial

Placebo group assumptions correct in phase IIb study of VLTS-934 in intermittent claudication

Novel orally active CB1 receptor inverse agonist decreases food intake in rodents

Novel orally active and in vivo effective p38alpha MAPK inhibitors from Novartis

FDA issues guidance to improve efficiency of earliest stages of clinical testing

Recent patents report novel therapeutic agents for anxiety, depression, etc.

Novel possible treatment options for cancer disclosed in patent literature

First launch for Dong-A erectile dysfunction therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...